{"id":4333,"date":"2025-10-31T12:32:44","date_gmt":"2025-10-31T07:02:44","guid":{"rendered":"https:\/\/blog.aquartia.in\/?p=4333"},"modified":"2025-10-31T12:32:45","modified_gmt":"2025-10-31T07:02:45","slug":"prip-scheme-from-generics-to-innovation-powerhouse","status":"publish","type":"post","link":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/","title":{"rendered":"PRIP Scheme: From Generics to Innovation Powerhouse"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Key Highlights<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India&#8217;s PRIP Scheme allocates\u00a0<strong>\u20b95000 crore<\/strong>\u00a0(2023-2028) to transition pharma from cost-based generics to innovation-driven growth<a href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li><strong>Seven Centres of Excellence<\/strong>\u00a0established at NIPERs focusing on anti-viral drugs, medical devices, biosimilars, and novel drug delivery systems<a href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Supports\u00a0<strong>~300 innovation projects<\/strong>\u00a0with total R&amp;D investment of\u00a0<strong>\u20b911,000 crore<\/strong>\u00a0in new chemical entities, biologics, gene therapy, and AI-powered MedTech<a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2173970\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Strategic focus on\u00a0<strong>orphan drugs, antimicrobial resistance<\/strong>, and precision medicines addressing India&#8217;s unmet healthcare needs<a href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Industry-academia collaboration incentivized with up to\u00a0<strong>50% funding support<\/strong>\u00a0for early-stage projects and\u00a0<strong>35% for later-stage<\/strong>\u00a0innovations<a href=\"https:\/\/www.pharmabiz.com\/NewsDetails.aspx?aid=181810&amp;sid=1\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">India at the Crossroads of Pharmaceutical Evolution<\/h2>\n\n\n\n<p>India has long worn the crown of the\u00a0<strong>&#8220;Pharmacy of the World&#8221;<\/strong>\u2014a title earned through decades of supplying\u00a0<strong>20% of global generic drugs<\/strong>\u00a0and\u00a0<strong>60% of the world&#8217;s vaccines<\/strong>. From meeting\u00a0<strong>40% of US generic demand<\/strong>\u00a0to providing\u00a0<strong>25% of all medicines in the UK<\/strong>, India&#8217;s pharmaceutical prowess in affordable healthcare is unmatched. With over\u00a0<strong>10,000 manufacturing facilities<\/strong>\u00a0and\u00a0<strong>670 USFDA-approved plants<\/strong>\u00a0(the highest outside the US), the nation has established itself as a volume giant in the global pharmaceutical landscape. <strong><a href=\"https:\/\/www.investindia.gov.in\/blogs\/pharmaceutical-sector-spotlight-driving-innovation-india\">investindia.gov\u200b<\/a><\/strong><\/p>\n\n\n\n<p>However, beneath this impressive facade lies a critical challenge. While India excels in&nbsp;<strong>cost-competitive generics production<\/strong>, it significantly lags behind global peers in&nbsp;<strong>innovation, R&amp;D intensity, and cutting-edge pharmaceutical research<\/strong>. Indian pharma companies invest merely&nbsp;<strong>5-8% of revenues<\/strong>&nbsp;in R&amp;D compared to&nbsp;<strong>15-20% by US firms<\/strong>&nbsp;and&nbsp;<strong>18-22% by European giants<\/strong>. Global firms outperform Indian counterparts by&nbsp;<strong>3.0x in R&amp;D intensity<\/strong>&nbsp;and generate&nbsp;<strong>5.6 times more patents<\/strong>&nbsp;per billion USD revenue.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/theprint.in\/economy\/indian-pharma-firms-trail-global-peers-in-rd-innovation-and-talent-metrics-fast-india-iifl-securities\/2320253\/\"><\/a>\u200b<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-239-1024x1024.png\" alt=\"\" class=\"wp-image-4334\" srcset=\"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-239-1024x1024.png 1024w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-239-300x300.png 300w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-239-150x150.png 150w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-239-768x768.png 768w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-239-1536x1536.png 1536w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-239.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>This innovation deficit poses existential risks as the global pharmaceutical industry pivots toward&nbsp;<strong>biologics, biosimilars, precision medicine, gene therapy<\/strong>, and&nbsp;<strong>AI-driven drug discovery<\/strong>. Countries like China, Brazil, and South Korea are rapidly scaling their innovation capacities, threatening India&#8217;s traditional generics dominance.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.ijdra.com\/index.php\/journal\/article\/view\/745\"><\/a>\u200b<\/p>\n\n\n\n<p>Enter the&nbsp;<strong>Promotion of Research &amp; Innovation in Pharma MedTech Sector (PRIP) Scheme<\/strong>\u2014notified in&nbsp;<strong>August 2023<\/strong>&nbsp;with a groundbreaking&nbsp;<strong>\u20b95000 crore outlay<\/strong>&nbsp;over five years (2023-2028). This transformative initiative represents India&#8217;s most ambitious attempt to reposition itself from a&nbsp;<strong>volume-based generics supplier<\/strong>&nbsp;to a&nbsp;<strong>value-driven innovation powerhouse<\/strong>&nbsp;capable of competing in high-value pharmaceutical segments globally.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">India&#8217;s Pharmaceutical Strengths: The Foundation for Transformation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Unparalleled Global Market Position<\/h3>\n\n\n\n<p>India&#8217;s pharmaceutical sector contributes&nbsp;<strong>1.72% to national GDP<\/strong>&nbsp;and stands as the&nbsp;<strong>world&#8217;s third-largest by volume<\/strong>&nbsp;and&nbsp;<strong>13th by value<\/strong>. The industry&#8217;s&nbsp;<strong>$50-55 billion valuation<\/strong>&nbsp;(FY 2023-24) is projected to reach&nbsp;<strong>$120-130 billion by 2030<\/strong>, potentially doubling its GDP contribution.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/en.wikipedia.org\/wiki\/Pharmaceutical_industry_in_India\"><\/a>\u200b<\/p>\n\n\n\n<p>The country manufactures&nbsp;<strong>60,000 generic brands across 60 therapeutic categories<\/strong>, supplying medicines to&nbsp;<strong>over 200 countries<\/strong>. India&#8217;s vaccine manufacturing capacity is particularly formidable\u2014producing&nbsp;<strong>40-70% of WHO&#8217;s demand<\/strong>&nbsp;for DPT and BCG vaccines and&nbsp;<strong>90% of measles vaccine requirements<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/upstox.com\/news\/upstox-originals\/investing\/india-s-global-prescription-the-rise-of-generic-drugs\/article-129583\/\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Cost-Competitive Manufacturing Excellence<\/h3>\n\n\n\n<p>India&#8217;s competitive advantage stems from its&nbsp;<strong>world-class manufacturing infrastructure<\/strong>&nbsp;combined with a&nbsp;<strong>skilled, cost-effective workforce<\/strong>. With a&nbsp;<strong>talent pool graduating thousands of science and engineering professionals annually<\/strong>, the nation maintains&nbsp;<strong>3,000+ pharma companies<\/strong>&nbsp;and over&nbsp;<strong>500 active pharmaceutical ingredient (API) manufacturers<\/strong>&nbsp;contributing&nbsp;<strong>8% to global API production<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.bain.com\/insights\/healing-the-world-a-roadmap-for-making-india-a-global-pharma-exports-hub\/\"><\/a>\u200b<\/p>\n\n\n\n<p>The cost arbitrage enables Indian manufacturers to produce&nbsp;<strong>high-quality medicines at 30-40% lower costs<\/strong>&nbsp;than Western counterparts, making treatments accessible to millions in developing nations.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.brickworkratings.com\/Research\/Drugsand%20Pharmaceuticals%20Industry-India-Nov2024.pdf\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">The Innovation Gap: Confronting India&#8217;s R&amp;D Crisis<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Low R&amp;D Intensity and Patent Output<\/h3>\n\n\n\n<p>Despite its manufacturing prowess, India&#8217;s pharmaceutical innovation metrics reveal a troubling picture. Research intensity averages a mere\u00a0<strong>0.7% of GDP in healthcare<\/strong>\u00a0compared to\u00a0<strong>2.5-3% in developed economies<\/strong>. Indian firms allocate\u00a0<strong>less than 2% of revenue<\/strong>\u00a0to R&amp;D against the global pharmaceutical industry standard of\u00a0<strong>15%+<\/strong>. <strong><a href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\">knnindia.co\u200b<\/a><\/strong><\/p>\n\n\n\n<p>This underinvestment manifests in stark innovation output gaps. Global pharmaceutical companies generate&nbsp;<strong>8.4 times more publications<\/strong>&nbsp;and&nbsp;<strong>5.6 times more patents<\/strong>&nbsp;per billion USD revenue than Indian firms. Only&nbsp;<strong>four Indian companies<\/strong>&nbsp;rank among the top performers for patents by revenue, with Dr. Reddy&#8217;s Laboratories leading domestic firms at&nbsp;<strong>10.3% R&amp;D intensity<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/theprint.in\/economy\/indian-pharma-firms-trail-global-peers-in-rd-innovation-and-talent-metrics-fast-india-iifl-securities\/2320253\/\"><\/a>\u200b<\/p>\n\n\n\n<p>NIPERs\u2014India&#8217;s premier pharmaceutical research institutes\u2014have collectively filed only&nbsp;<strong>425 patents<\/strong>&nbsp;and published&nbsp;<strong>8,048 research papers<\/strong>&nbsp;since inception, a fraction of output from comparable international institutions.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/sansad.in\/getFile\/loksabhaquestions\/annex\/183\/AU760_Ww9LQl.pdf\"><\/a>\u200b<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-240-1024x1024.png\" alt=\"\" class=\"wp-image-4335\" srcset=\"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-240-1024x1024.png 1024w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-240-300x300.png 300w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-240-150x150.png 150w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-240-768x768.png 768w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-240-1536x1536.png 1536w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/image-240.png 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\">Regulatory Barriers and Infrastructure Gaps<\/h3>\n\n\n\n<p>The innovation ecosystem faces multiple structural challenges. India&#8217;s&nbsp;<strong>patent law tensions<\/strong>&nbsp;between access-to-medicines principles and innovator incentives create uncertainty for R&amp;D investments. The revised&nbsp;<strong>Schedule M GMP compliance requirements<\/strong>\u2014aligning India with WHO standards\u2014demand significant infrastructure upgrades, particularly challenging for&nbsp;<strong>8,500+ small and medium pharmaceutical units<\/strong>&nbsp;granted extensions until&nbsp;<strong>December 2025<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.ijfmr.com\/research-paper.php?id=32114\"><\/a>\u200b<\/p>\n\n\n\n<p>Regulatory approval processes for new drugs remain slower than global benchmarks, and&nbsp;<strong>weak IP enforcement<\/strong>&nbsp;historically discouraged proprietary innovation.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/1331677X.2017.1311223?needAccess=true\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Competition from Emerging Pharma Powers<\/h3>\n\n\n\n<p>China has emerged as a formidable competitor, with firms now spending&nbsp;<strong>8-10% of revenues on R&amp;D<\/strong>&nbsp;backed by&nbsp;<strong>massive state-funded innovation programs<\/strong>. Chinese pharmaceutical patents have proliferated across&nbsp;<strong>biotechnology, AI, and biologics<\/strong>. Brazil and South Korea similarly accelerated innovation capacities through strategic government interventions.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.linkedin.com\/posts\/sheetal-sharma-803069205_indias-pharma-rd-spending-a-global-comparison-activity-7383869118766071808-Iom1\"><\/a>\u200b<\/p>\n\n\n\n<p>India risks missing the&nbsp;<strong>biotechnology wave<\/strong>&nbsp;unless it rapidly scales innovation capabilities.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.nature.com\/articles\/nbt.2380\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">PRIP Scheme: Architecture of India&#8217;s Innovation Transformation<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Vision and Strategic Objectives<\/h3>\n\n\n\n<p>The PRIP Scheme embodies a fundamental strategic pivot\u2014transforming Indian pharma from&nbsp;<strong>cost-based competitiveness to innovation-based growth<\/strong>. Core objectives include:<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Strengthening\u00a0<strong>R&amp;D infrastructure<\/strong>\u00a0through world-class research facilities<a href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Promoting\u00a0<strong>industry-academia linkages<\/strong>\u00a0for translational research<a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1960812\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Nurturing a\u00a0<strong>culture of quality research<\/strong>\u00a0and retaining scientific talent<a href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Building\u00a0<strong>sustained global competitive advantage<\/strong>\u00a0in high-value pharmaceutical segments<a href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Encouraging innovation for\u00a0<strong>human and animal health<\/strong>\u00a0with focus on unmet medical needs<a href=\"https:\/\/www.rarediseases.in\/india-launches-pharma-medtech-prip-schemes-to-boost-rd-in-rare-disease-sector\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Governance Framework: Multi-Stakeholder Oversight<\/h3>\n\n\n\n<p>An&nbsp;<strong>Empowered Committee<\/strong>&nbsp;chaired by the&nbsp;<strong>CEO of NITI Aayog<\/strong>&nbsp;provides strategic guidance, comprising secretaries from:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Department of Pharmaceuticals<\/li>\n\n\n\n<li>Ministry of Health &amp; Family Welfare<\/li>\n\n\n\n<li>Indian Council of Medical Research (ICMR)<\/li>\n\n\n\n<li>Department of Biotechnology (DBT)<\/li>\n\n\n\n<li>Council of Scientific and Industrial Research (CSIR)<\/li>\n\n\n\n<li>AYUSH and Department of Science &amp; Technology (DST)<a href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<p>This multi-ministerial structure ensures alignment across government, academia, and industry stakeholders.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Component A: Centres of Excellence at NIPERs<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Infrastructure Investment<\/h3>\n\n\n\n<p>Component A allocates\u00a0<strong>\u20b9700 crore<\/strong>\u00a0over five years to establish\u00a0<strong>seven Centres of Excellence (CoEs)<\/strong>, one at each existing NIPER. As of 2024, these CoEs have\u00a0<strong>approved 104 research projects<\/strong>\u00a0and\u00a0<strong>filed 2 patents<\/strong>, with ongoing infrastructure development. <strong><a href=\"https:\/\/www.pib.gov.in\/PressReleaseIframePage.aspx?PRID=2085345\">pib.gov<\/a><\/strong><a href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Strategic Specializations Across Seven NIPERs<\/h4>\n\n\n\n<p>Each CoE focuses on distinct high-priority research domains:<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th><strong>NIPER Location<\/strong><\/th><th><strong>Centre of Excellence Specialization<\/strong><\/th><\/tr><\/thead><tbody><tr><td><strong>NIPER Mohali<\/strong><\/td><td>Anti-viral and Anti-bacterial Drug Discovery &amp; Development<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/td><\/tr><tr><td><strong>NIPER Ahmedabad<\/strong><\/td><td>Medical Devices and Diagnostics<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/td><\/tr><tr><td><strong>NIPER Hyderabad<\/strong><\/td><td>Bulk Drugs and API Manufacturing<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/td><\/tr><tr><td><strong>NIPER Kolkata<\/strong><\/td><td>Flow Chemistry and Continuous Manufacturing<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/td><\/tr><tr><td><strong>NIPER Raebareli<\/strong><\/td><td>Novel Drug Delivery Systems (NDDS)<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/niperraebareli.edu.in\/coe.html\"><\/a>\u200b<\/td><\/tr><tr><td><strong>NIPER Guwahati<\/strong><\/td><td>Phyto-pharmaceuticals and Natural Products<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/td><\/tr><tr><td><strong>NIPER Hajipur<\/strong><\/td><td>Biological Therapeutics and Biosimilars<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>These specializations address critical gaps\u2014from&nbsp;<strong>antimicrobial resistance (AMR)<\/strong>&nbsp;drug development to&nbsp;<strong>affordable medical devices<\/strong>&nbsp;and&nbsp;<strong>biosimilar production<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Accelerating Industry-Academia Knowledge Transfer<\/h3>\n\n\n\n<p>CoEs serve as&nbsp;<strong>bridges between academic research and commercial applications<\/strong>. NIPER Raebareli&#8217;s NDDS Centre aims to overcome limitations of existing drug delivery systems through&nbsp;<strong>consultancy, contract research<\/strong>, and industry collaboration to&nbsp;<strong>translate research to market<\/strong>. Similar initiatives at other NIPERs include&nbsp;<strong>303+ MOUs with industries<\/strong>&nbsp;and academic institutions.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/sansad.in\/getFile\/loksabhaquestions\/annex\/183\/AU760_Ww9LQl.pdf\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Component B: Priority Research Funding for Innovation Projects<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">\u20b94,250 Crore for Breakthrough Research<\/h3>\n\n\n\n<p>Component B allocates\u00a0<strong>\u20b94,250 crore<\/strong>\u00a0to support industry and startup-led R&amp;D in collaboration with academic institutions. The scheme targets\u00a0<strong>~300 innovation projects<\/strong>\u00a0catalyzing\u00a0<strong>\u20b911,000 crore total R&amp;D investment<\/strong>. <strong><a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2173970\">PRIPscheme<\/a><\/strong>\u00a0<a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2173970\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Six Strategic Priority Research Areas<\/h3>\n\n\n\n<p>Funding focuses on six transformative domains:<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>1. New Chemical Entities (NCEs):<\/strong>&nbsp;Including biologics, biosimilars, and phytopharmaceuticals\u2014addressing India&#8217;s negligible contribution to novel drug discovery<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.rarediseases.in\/india-launches-pharma-medtech-prip-schemes-to-boost-rd-in-rare-disease-sector\/\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>2. Complex Generics and Biosimilars:<\/strong>&nbsp;Leveraging India&#8217;s manufacturing expertise to capture high-value segments as blockbuster biologics approach patent cliffs (Opdivo 2028, Keytruda 2028)<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.ipa-india.org\/sites\/default\/files\/2025-07\/whitepaper-6th-biopharma-conclave-2024.pdf\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>3. Precision Medicines:<\/strong>&nbsp;Gene therapy, stem cell technologies, and personalized treatments\u2014domains requiring cutting-edge capabilities<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>4. AI\/ML-Powered Medical Devices:<\/strong>&nbsp;Next-generation diagnostics and therapeutics utilizing artificial intelligence and machine learning<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>5. Orphan Drugs for Rare Diseases:<\/strong>&nbsp;Addressing&nbsp;<strong>72-96 million Indians<\/strong>&nbsp;affected by&nbsp;<strong>450+ rare diseases<\/strong>&nbsp;with limited treatment options<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10529578\/\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>6. Antimicrobial Resistance (AMR):<\/strong>&nbsp;Critical global health priority where India faces&nbsp;<strong>600,000 annual deaths<\/strong>&nbsp;from resistant infections<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleaseIframePage.aspx?PRID=2081506\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Tiered Financial Support Structure<\/h3>\n\n\n\n<p>The amended scheme (September 2024) provides differentiated funding:<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>Early-Stage Projects (up to \u20b99 crore):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>100% assistance<\/strong>\u00a0for costs up to\u00a0<strong>\u20b91 crore<\/strong><\/li>\n\n\n\n<li><strong>50% assistance<\/strong>\u00a0for additional costs beyond \u20b91 crore<\/li>\n\n\n\n<li><strong>Maximum support: \u20b95 crore<\/strong><a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2173970\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<p><strong>Later-Stage Projects (up to \u20b9285 crore):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>35% of project cost<\/strong>\u00a0as standard assistance<\/li>\n\n\n\n<li><strong>Maximum support: \u20b9100 crore<\/strong><a href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<p><strong>Strategic Priority Innovation (SPI) Areas:<\/strong><br>For orphan drugs, AMR, vaccine-preventable diseases, vector-borne diseases, and pandemic pathogens:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Up to 50% assistance<\/strong><\/li>\n\n\n\n<li><strong>Maximum \u20b9100 crore<\/strong>\u00a0for later-stage projects<a href=\"https:\/\/pharma.economictimes.indiatimes.com\/news\/policy-and-regulations\/government-eyes-modifications-to-prip-scheme-for-rare-disease-therapies\/123412212\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Industry-Academia Collaboration Incentives<\/h3>\n\n\n\n<p>The scheme prioritizes partnerships between&nbsp;<strong>industry\/startups<\/strong>&nbsp;and&nbsp;<strong>reputed academic\/government research institutions<\/strong>. Up to&nbsp;<strong>nine projects each<\/strong>&nbsp;at early and later stages receive&nbsp;<strong>selection preference<\/strong>&nbsp;for strong collaborative development. Firms may&nbsp;<strong>in-license research outputs<\/strong>&nbsp;from academic institutions using scheme funds, creating viable pathways from lab to market.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleseDetailm.aspx?PRID=2173970\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Enabling Ecosystem: Patent Mitra and MedTech Mitra<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Medical Innovations Patent Mitra<\/h3>\n\n\n\n<p>Launched by ICMR in&nbsp;<strong>March 2025<\/strong>,&nbsp;<strong>Patent Mitra<\/strong>&nbsp;provides&nbsp;<strong>end-to-end patent filing support<\/strong>&nbsp;to biomedical innovators. The initiative offers:<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2163759\"><\/a>\u200b<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patentability assessments<\/strong>\u00a0and strategic IP guidance<a href=\"https:\/\/www.icmr.gov.in\/icmrobject\/uploads\/Documents\/1743077403_pressrelease.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li><strong>Patent filing, prosecution<\/strong>, and maintenance support<a href=\"https:\/\/patentmitra.icmr.org.in\/static\/pdf\/Patent%20Mitra_Launch%20Report.pdf\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li><strong>Technology transfer facilitation<\/strong>\u00a0to industry partners<a href=\"https:\/\/health.economictimes.indiatimes.com\/news\/industry\/icmr-launches-medical-innovations-patent-mitra-to-support-biomedical-innovations\/118814226\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<p>At the&nbsp;<strong>India MedTech Expo 2025<\/strong>, ICMR licensed&nbsp;<strong>nine cutting-edge technologies<\/strong>&nbsp;under Patent Mitra, resulting in&nbsp;<strong>17 licensing deals<\/strong>&nbsp;for infectious disease diagnostics, immunodiagnostics, and vaccines.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.newsonair.gov.in\/icmr-licenses-nine-medical-technologies-to-industry-partners-at-india-medtech-expo-2025\/\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">MedTech Mitra: Accelerating Medical Device Innovation<\/h3>\n\n\n\n<p><strong>MedTech Mitra<\/strong>&nbsp;supports&nbsp;<strong>startups and industry<\/strong>&nbsp;in developing&nbsp;<strong>regulation-compliant Indian MedTech products<\/strong>. The platform provides regulatory navigation, testing support, and market access guidance\u2014critical for scaling indigenous medical devices.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleseDetailm.aspx?PRID=2173970\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Pan-India Digital Innovation Exchange<\/h3>\n\n\n\n<p>PRIP envisions a&nbsp;<strong>digital Pharma-MedTech innovation exchange<\/strong>&nbsp;connecting innovators with:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Investors and venture capital<\/strong><\/li>\n\n\n\n<li><strong>Mentors and industry experts<\/strong><\/li>\n\n\n\n<li>Government initiatives (Patent Mitra, MedTech Mitra)<\/li>\n\n\n\n<li><strong>Global collaboration opportunities<\/strong><a href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<p>This ecosystem approach ensures comprehensive support from&nbsp;<strong>idea to market<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Expected Impact: Transforming India&#8217;s Pharmaceutical Landscape<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">For Industry: De-Risking Innovation<\/h3>\n\n\n\n<p>PRIP&nbsp;<strong>financially de-risks<\/strong>&nbsp;costly, long-term R&amp;D, making innovation&nbsp;<strong>feasible for MSMEs and startups<\/strong>. By offsetting 35-50% of project costs, the scheme enables smaller firms to compete in&nbsp;<strong>biologics, biosimilars<\/strong>, and novel therapeutics\u2014segments previously dominated by multinational corporations.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<p>The initiative creates a&nbsp;<strong>robust innovation pipeline<\/strong>&nbsp;for original drugs, complex generics, and medical devices, potentially generating&nbsp;<strong>thousands of high-skill jobs<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">For Academia: World-Class Research Infrastructure<\/h3>\n\n\n\n<p>NIPERs gain&nbsp;<strong>state-of-the-art facilities<\/strong>&nbsp;rivaling international institutions. Upgraded infrastructure attracts&nbsp;<strong>top talent<\/strong>, including&nbsp;<strong>overseas researchers returning to India<\/strong>, while collaborative funding opportunities encourage&nbsp;<strong>publication of high-impact research<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.expresspharma.in\/govt-provides-update-on-schemes-implemented-in-the-pharma-sector\/\"><\/a>\u200b<\/p>\n\n\n\n<p>NIPER graduates\u2014currently&nbsp;<strong>10,960 alumni<\/strong>\u2014provide a skilled workforce to industry and R&amp;D organizations.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/sansad.in\/getFile\/loksabhaquestions\/annex\/183\/AU760_Ww9LQl.pdf\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">For India&#8217;s Global Standing: Value-Chain Ascension<\/h3>\n\n\n\n<p>PRIP positions India to move&nbsp;<strong>up the pharmaceutical value chain<\/strong>\u2014from generics supplier to&nbsp;<strong>drug innovator and MedTech hub<\/strong>. Success in biosimilars (where India already has&nbsp;<strong>95+ CDSCO-approved products<\/strong>) and entry into precision medicine could significantly&nbsp;<strong>enhance export value<\/strong>&nbsp;beyond current&nbsp;<strong>$25.3 billion<\/strong>&nbsp;(FY 2022-23).<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/en.wikipedia.org\/wiki\/Pharmaceutical_industry_in_India\"><\/a>\u200b<\/p>\n\n\n\n<p>Enhanced&nbsp;<strong>global reputation<\/strong>&nbsp;attracts&nbsp;<strong>foreign investment<\/strong>&nbsp;and strengthens India&#8217;s role in international health security frameworks\u2014from&nbsp;<strong>G20 health priorities<\/strong>&nbsp;to&nbsp;<strong>WHO global health initiatives<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1929936\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">For Society: Affordable Innovation for Unmet Needs<\/h3>\n\n\n\n<p>PRIP directs innovation toward&nbsp;<strong>critical public health priorities<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Rare diseases<\/strong>\u00a0affecting 72-96 million Indians with limited treatment access<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10529578\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li><strong>Antimicrobial resistance<\/strong>\u2014a crisis claiming 600,000 Indian lives annually<a href=\"https:\/\/www.pib.gov.in\/PressReleaseIframePage.aspx?PRID=2081506\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li><strong>Affordable medical devices<\/strong>\u00a0for rural and underserved populations<a href=\"https:\/\/www.frontiersin.org\/articles\/10.3389\/fdgth.2023.1268010\/pdf?isPublishedV2=False\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li><strong>Vaccine development<\/strong>\u00a0for pandemic preparedness<a href=\"https:\/\/www.path.org\/our-impact\/path-events\/how-path-is-supporting-indias-g20-presidency\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<p>By incentivizing&nbsp;<strong>orphan drug development<\/strong>&nbsp;and&nbsp;<strong>AMR-focused research<\/strong>, PRIP ensures innovations serve both&nbsp;<strong>commercial viability<\/strong>&nbsp;and&nbsp;<strong>societal impact<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/news\/policy-and-regulations\/government-eyes-modifications-to-prip-scheme-for-rare-disease-therapies\/123412212\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Challenges and Critical Success Factors<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Intellectual Property and Regulatory Harmonization<\/h3>\n\n\n\n<p>India&#8217;s&nbsp;<strong>patent regime<\/strong>&nbsp;must balance&nbsp;<strong>access-to-medicines principles<\/strong>&nbsp;with sufficient&nbsp;<strong>innovator incentives<\/strong>. Streamlining&nbsp;<strong>patent processes<\/strong>&nbsp;and providing&nbsp;<strong>fast-track reviews<\/strong>&nbsp;for PRIP-supported innovations will accelerate commercialization.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleaseIframePage.aspx?PRID=2085345\"><\/a>\u200b<\/p>\n\n\n\n<p>The&nbsp;<strong>Schedule M revision<\/strong>\u2014bringing GMP standards to WHO-PIC\/S levels\u2014demands significant compliance investments, particularly for&nbsp;<strong>8,500 SME units<\/strong>. Sustained financial and technical support is essential to prevent quality gaps.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/pharmastate.academy\/revised-schedule-m-complete-guide-to-pharma-compliance\/\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Sustained Funding and Project Selection<\/h3>\n\n\n\n<p>Ensuring&nbsp;<strong>transparent, merit-based project selection<\/strong>&nbsp;and&nbsp;<strong>timely fund disbursement<\/strong>&nbsp;will determine PRIP&#8217;s credibility. Realistic assessment of&nbsp;<strong>commercial viability<\/strong>&nbsp;and&nbsp;<strong>public health impact<\/strong>&nbsp;should guide funding decisions.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/pharma.economictimes.indiatimes.com\/news\/policy-and-regulations\/government-eyes-modifications-to-prip-scheme-for-rare-disease-therapies\/123412212\"><\/a>\u200b<\/p>\n\n\n\n<p>India&#8217;s historically&nbsp;<strong>low R&amp;D spend (&lt;2% of pharma revenue)<\/strong>&nbsp;requires cultural transformation. Industry must commit matching investments beyond government support.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Global Competition and Talent Retention<\/h3>\n\n\n\n<p>China&#8217;s&nbsp;<strong>8-10% R&amp;D intensity<\/strong>&nbsp;and&nbsp;<strong>massive state-backed innovation funds<\/strong>&nbsp;set aggressive benchmarks. Brazil and South Korea similarly accelerate pharmaceutical capabilities.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.linkedin.com\/posts\/sheetal-sharma-803069205_indias-pharma-rd-spending-a-global-comparison-activity-7383869118766071808-Iom1\"><\/a>\u200b<\/p>\n\n\n\n<p>India must&nbsp;<strong>attract and retain global talent<\/strong>, preventing&nbsp;<strong>brain drain<\/strong>&nbsp;while encouraging&nbsp;<strong>diaspora researchers<\/strong>&nbsp;to return. Competitive salaries, world-class facilities, and intellectual freedom are prerequisites.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1960812\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Industry-Academia Collaboration Quality<\/h3>\n\n\n\n<p>While PRIP incentivizes partnerships,&nbsp;<strong>meaningful collaboration<\/strong>&nbsp;requires cultural shifts. Industry must move beyond&nbsp;<strong>transactional relationships<\/strong>&nbsp;to genuine&nbsp;<strong>co-development<\/strong>&nbsp;models. Academic institutions need flexibility in&nbsp;<strong>IP sharing<\/strong>&nbsp;and&nbsp;<strong>commercialization<\/strong>&nbsp;processes.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/sansad.in\/getFile\/loksabhaquestions\/annex\/183\/AU760_Ww9LQl.pdf\"><\/a>\u200b<\/p>\n\n\n\n<p>The&nbsp;<strong>NIPER Academia-Industry Coordination Committee<\/strong>&nbsp;aims to institutionalize linkages, but success depends on sustained engagement.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleseDetailm.aspx?PRID=2173970\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Global Comparative Perspective<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">US and Europe: Deep IP Protection and R&amp;D Investment<\/h3>\n\n\n\n<p>Western pharmaceutical giants invest&nbsp;<strong>15-22% of revenues<\/strong>&nbsp;in R&amp;D, protected by&nbsp;<strong>robust IP regimes<\/strong>&nbsp;and&nbsp;<strong>fast regulatory approvals<\/strong>. Pfizer, Roche, and Novartis maintain multi-billion dollar research budgets, filing&nbsp;<strong>hundreds of patents annually<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/theprint.in\/economy\/indian-pharma-firms-trail-global-peers-in-rd-innovation-and-talent-metrics-fast-india-iifl-securities\/2320253\/\"><\/a>\u200b<\/p>\n\n\n\n<p><strong>Academia-industry partnerships<\/strong>&nbsp;are deeply embedded\u2014US universities generate&nbsp;<strong>significant licensing revenues<\/strong>&nbsp;from pharmaceutical innovations.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/C8FABCDC2FD7DBC3F37F7E2129F15641\/S2059866121000017a.pdf\/div-class-title-advancing-medical-technology-innovation-and-clinical-translation-via-a-model-of-industry-enabled-technical-and-educational-support-indiana-clinical-and-translational-sciences-institute-s-medical-technology-advance-program-div.pdf\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">China: State-Backed Innovation Juggernaut<\/h3>\n\n\n\n<p>China&#8217;s pharmaceutical innovation acceleration stems from&nbsp;<strong>massive government funding<\/strong>,&nbsp;<strong>integrated manufacturing-research complexes<\/strong>, and&nbsp;<strong>rapid regulatory reforms<\/strong>. Chinese firms now spend&nbsp;<strong>8-10% of revenues on R&amp;D<\/strong>\u2014double India&#8217;s average\u2014with strong focus on&nbsp;<strong>biologics, AI-driven drug discovery<\/strong>, and&nbsp;<strong>biosimilars<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.linkedin.com\/posts\/sheetal-sharma-803069205_indias-pharma-rd-spending-a-global-comparison-activity-7383869118766071808-Iom1\"><\/a>\u200b<\/p>\n\n\n\n<p>China&#8217;s&nbsp;<strong>patent filings in biotechnology<\/strong>&nbsp;and&nbsp;<strong>precision medicine<\/strong>&nbsp;have surged, positioning the nation as a formidable innovation competitor.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.nature.com\/articles\/nbt.2380\"><\/a>\u200b<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">India&#8217;s Hybrid Model: Leveraging Cost Advantage<\/h3>\n\n\n\n<p>PRIP attempts a&nbsp;<strong>balanced approach<\/strong>\u2014building on India&#8217;s&nbsp;<strong>cost-competitive manufacturing<\/strong>&nbsp;while investing strategically in&nbsp;<strong>high-value innovation<\/strong>. Unlike China&#8217;s top-down state control, India emphasizes&nbsp;<strong>public-private partnerships<\/strong>&nbsp;and&nbsp;<strong>decentralized innovation ecosystems<\/strong>.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<p>Success requires&nbsp;<strong>sustained political will<\/strong>,&nbsp;<strong>regulatory consistency<\/strong>, and&nbsp;<strong>industry commitment<\/strong>&nbsp;matching global benchmarks.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1960812\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Policy Roadmap: Actionable Recommendations<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">1. Holistic Regulatory Reform<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fast-track approval processes<\/strong>\u00a0for PRIP-supported innovations, reducing time-to-market<a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1960812\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li><strong>Harmonize domestic GMP standards<\/strong>\u00a0with WHO-PIC\/S globally, ensuring export competitiveness<a href=\"https:\/\/pharmastate.academy\/revised-schedule-m-complete-guide-to-pharma-compliance\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Establish\u00a0<strong>dedicated regulatory pathways<\/strong>\u00a0for orphan drugs, biosimilars, and precision medicines<a href=\"https:\/\/www.ijdra.com\/index.php\/journal\/article\/view\/745\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. IPR Ecosystem Strengthening<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Simplify patent filing<\/strong>\u00a0and reduce costs for startups and MSMEs<a href=\"https:\/\/spicyip.com\/2024\/06\/an-assessment-of-the-national-policy-on-research-development-and-innovation-in-the-pharma-med-tech-sector-in-india.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Incentivize\u00a0<strong>IP creation<\/strong>\u00a0through tax benefits and grant preferences<a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1960812\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Leverage\u00a0<strong>Patent Mitra<\/strong>\u00a0for comprehensive IP support across biomedical innovations<a href=\"https:\/\/health.economictimes.indiatimes.com\/news\/industry\/icmr-launches-medical-innovations-patent-mitra-to-support-biomedical-innovations\/118814226\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>3. Deepening Industry-Academia Linkages<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Establish\u00a0<strong>regional technology transfer cells<\/strong>\u00a0at all NIPERs for commercializing academic inventions<a href=\"https:\/\/www.pib.gov.in\/PressReleseDetailm.aspx?PRID=2173970\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Host\u00a0<strong>innovation hackathons<\/strong>\u00a0and challenge funds modeled on global best practices<a href=\"https:\/\/spicyip.com\/2024\/06\/an-assessment-of-the-national-policy-on-research-development-and-innovation-in-the-pharma-med-tech-sector-in-india.html\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Create\u00a0<strong>flexible IP-sharing frameworks<\/strong>\u00a0balancing academic freedom and commercial returns<a href=\"https:\/\/www.pharmabiz.com\/NewsDetails.aspx?aid=170181&amp;sid=1\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">4. Infrastructure and Sustained Funding<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Ensure\u00a0<strong>transparent PRIP fund disbursement<\/strong>\u00a0with clear milestones and accountability<a href=\"https:\/\/www.pib.gov.in\/PressReleaseIframePage.aspx?PRID=2085345\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Foster\u00a0<strong>MedTech hubs<\/strong>\u00a0at all NIPERs, integrating device innovation with pharmaceutical research<a href=\"https:\/\/www.studyiq.com\/articles\/prip-scheme\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Support\u00a0<strong>MSMEs through soft loans<\/strong>, technical training, and regulatory compliance assistance<a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=2173970\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">5. Global Collaboration and Market Access<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Enter\u00a0<strong>co-development agreements<\/strong>\u00a0with EU\/US\/Japan pharma for joint research on global health priorities<a href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1929936\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Leverage\u00a0<strong>G20 and WHO channels<\/strong>\u00a0for collaborative vaccine and diagnostics development<a href=\"https:\/\/www.path.org\/our-impact\/path-events\/how-path-is-supporting-indias-g20-presidency\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Participate in\u00a0<strong>international clinical trials<\/strong>\u00a0to validate Indian innovations globally<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4215498\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">6. MSME Capacity Building<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Provide\u00a0<strong>GMP compliance training<\/strong>\u00a0and infrastructure grants for Schedule M adherence<a href=\"https:\/\/www.india-briefing.com\/news\/india-extends-gmp-compliance-deadline-to-december-2025-35679.html\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Create\u00a0<strong>MSME consortia<\/strong>\u00a0for joint R&amp;D and product development, pooling resources<a href=\"https:\/\/www.rarediseases.in\/india-launches-pharma-medtech-prip-schemes-to-boost-rd-in-rare-disease-sector\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Facilitate\u00a0<strong>access to advanced testing facilities<\/strong>\u00a0and analytical equipment at NIPERs<a href=\"https:\/\/www.expresspharma.in\/govt-provides-update-on-schemes-implemented-in-the-pharma-sector\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">7. Ethical Innovation and Social Responsibility<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Mandate\u00a0<strong>orphan drug development<\/strong>\u00a0and\u00a0<strong>AMR-focused research<\/strong>\u00a0as key PRIP performance metrics<a href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Prioritize\u00a0<strong>affordable innovation<\/strong>\u00a0addressing India&#8217;s disease burden (TB, malaria, NCDs)<a href=\"https:\/\/www.pib.gov.in\/PressReleaseIframePage.aspx?PRID=2081506\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n\n\n\n<li>Ensure\u00a0<strong>equitable access mechanisms<\/strong>\u00a0for therapies developed with public funding<a href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10529578\/\" target=\"_blank\" rel=\"noreferrer noopener\"><\/a>\u200b<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<h2 class=\"wp-block-heading\">Conclusion: A Defining Moment for Indian Pharma<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"1024\" src=\"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/dc93ab83-bbe5-47dd-b29a-9f5028f91244-1024x1024.jpg\" alt=\"\" class=\"wp-image-4337\" srcset=\"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/dc93ab83-bbe5-47dd-b29a-9f5028f91244-1024x1024.jpg 1024w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/dc93ab83-bbe5-47dd-b29a-9f5028f91244-300x300.jpg 300w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/dc93ab83-bbe5-47dd-b29a-9f5028f91244-150x150.jpg 150w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/dc93ab83-bbe5-47dd-b29a-9f5028f91244-768x768.jpg 768w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/dc93ab83-bbe5-47dd-b29a-9f5028f91244-1536x1536.jpg 1536w, https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/dc93ab83-bbe5-47dd-b29a-9f5028f91244.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The&nbsp;<strong>PRIP Scheme<\/strong>&nbsp;represents a&nbsp;<strong>watershed moment<\/strong>&nbsp;in India&#8217;s pharmaceutical journey\u2014a deliberate, strategic pivot from&nbsp;<strong>volume-based generics dominance<\/strong>&nbsp;to&nbsp;<strong>value-driven innovation leadership<\/strong>. With its&nbsp;<strong>\u20b95000 crore outlay<\/strong>, dual focus on&nbsp;<strong>research infrastructure (CoEs) and priority R&amp;D funding<\/strong>, and comprehensive ecosystem support through&nbsp;<strong>Patent Mitra and MedTech Mitra<\/strong>, PRIP provides the architecture for transformative change.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/vajiramandravi.com\/current-affairs\/prip-promotion-of-research-and-innovation-in-pharma-medtech-sector-scheme\/\"><\/a>\u200b<\/p>\n\n\n\n<p>However, implementation will determine destiny. India must navigate&nbsp;<strong>complex IPR challenges<\/strong>, ensure&nbsp;<strong>sustained funding and transparent governance<\/strong>, foster&nbsp;<strong>genuine industry-academia collaboration<\/strong>, and compete against&nbsp;<strong>aggressive global peers<\/strong>&nbsp;like China and Brazil. The&nbsp;<strong>Schedule M compliance deadline<\/strong>&nbsp;tests the sector&#8217;s quality commitment, while&nbsp;<strong>rare disease and AMR focus<\/strong>&nbsp;reflects social responsibility imperatives.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/knnindia.co.in\/news\/newsdetails\/sectors\/others\/rs-5000-cr-prip-scheme-launched-to-drive-pharma-medtech-innovation-supports-300-rd-projects\"><\/a>\u200b<\/p>\n\n\n\n<p>Success will require&nbsp;<strong>political consistency<\/strong>,&nbsp;<strong>industry investment matching government support<\/strong>,&nbsp;<strong>academic entrepreneurialism<\/strong>, and&nbsp;<strong>regulatory agility<\/strong>. If executed effectively, PRIP can help India achieve twin goals\u2014<strong>maintaining its generics legacy<\/strong>&nbsp;(critical for global affordable healthcare) while&nbsp;<strong>becoming a true innovation powerhouse<\/strong>&nbsp;in biologics, precision medicine, and next-generation therapeutics.<a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.bain.com\/insights\/healing-the-world-a-roadmap-for-making-india-a-global-pharma-exports-hub\/\"><\/a>\u200b<\/p>\n\n\n\n<p>As&nbsp;<strong>Dr. Mansukh Mandaviya<\/strong>&nbsp;stated at PRIP&#8217;s launch, &#8220;This is an inflection point in the journey of Atmanirbharta in pharma and medical devices&#8221;. The coming years will reveal whether India can leverage its&nbsp;<strong>manufacturing prowess, scientific talent<\/strong>, and&nbsp;<strong>innovation ecosystem investments<\/strong>&nbsp;to ascend the global pharmaceutical value chain\u2014transforming from the&nbsp;<strong>&#8220;Pharmacy of the World&#8221;<\/strong>&nbsp;to the&nbsp;<strong>&#8220;Innovation Lab of the World.&#8221;<\/strong><a rel=\"noreferrer noopener\" target=\"_blank\" href=\"https:\/\/www.pib.gov.in\/PressReleasePage.aspx?PRID=1960812\"><\/a>\u200b<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n","protected":false},"excerpt":{"rendered":"<p>Key Highlights India at the Crossroads of Pharmaceutical Evolution India has long worn the crown of the\u00a0&#8220;Pharmacy of the World&#8221;\u2014a title earned through decades of supplying\u00a020% of global generic drugs\u00a0and\u00a060% of the world&#8217;s vaccines. From meeting\u00a040% of US generic demand\u00a0to providing\u00a025% of all medicines in the UK, India&#8217;s pharmaceutical prowess in affordable healthcare is unmatched. <a href=\"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/\" class=\"read-more-link\">[Read More&#8230;]<\/a><\/p>\n","protected":false},"author":1,"featured_media":4336,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,975],"tags":[],"class_list":["post-4333","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog","category-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>PRIP Scheme: From Generics to Innovation Powerhouse - Aquartia Blog<\/title>\n<meta name=\"description\" content=\"Explore how India&#039;s PRIP Scheme is transforming pharma from generics leader to innovation hub with R&amp;D, biosimilars, precision medicine.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PRIP Scheme: From Generics to Innovation Powerhouse - Aquartia Blog\" \/>\n<meta property=\"og:description\" content=\"Explore how India&#039;s PRIP Scheme is transforming pharma from generics leader to innovation hub with R&amp;D, biosimilars, precision medicine.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/\" \/>\n<meta property=\"og:site_name\" content=\"Aquartia Blog\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/aquartiatechnology\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T07:02:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-31T07:02:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/Gemini_Generated_Image_huvjyshuvjyshuvj.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Siddharth Srivastava\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Siddharth Srivastava\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/\"},\"author\":{\"name\":\"Siddharth Srivastava\",\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/#\\\/schema\\\/person\\\/8160a5b038855c9fdcc1de41b2310004\"},\"headline\":\"PRIP Scheme: From Generics to Innovation Powerhouse\",\"datePublished\":\"2025-10-31T07:02:44+00:00\",\"dateModified\":\"2025-10-31T07:02:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/\"},\"wordCount\":2914,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blog.aquartia.in\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Gemini_Generated_Image_huvjyshuvjyshuvj.png\",\"articleSection\":[\"Blog\",\"Medicine\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/\",\"url\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/\",\"name\":\"PRIP Scheme: From Generics to Innovation Powerhouse - Aquartia Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blog.aquartia.in\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Gemini_Generated_Image_huvjyshuvjyshuvj.png\",\"datePublished\":\"2025-10-31T07:02:44+00:00\",\"dateModified\":\"2025-10-31T07:02:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/#\\\/schema\\\/person\\\/8160a5b038855c9fdcc1de41b2310004\"},\"description\":\"Explore how India's PRIP Scheme is transforming pharma from generics leader to innovation hub with R&D, biosimilars, precision medicine.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blog.aquartia.in\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Gemini_Generated_Image_huvjyshuvjyshuvj.png\",\"contentUrl\":\"https:\\\/\\\/blog.aquartia.in\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Gemini_Generated_Image_huvjyshuvjyshuvj.png\",\"width\":1024,\"height\":1024,\"caption\":\"India's PRIP Scheme ignites pharmaceutical R&D, moving beyond generics.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/2025\\\/10\\\/31\\\/prip-scheme-from-generics-to-innovation-powerhouse\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blog.aquartia.in\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRIP Scheme: From Generics to Innovation Powerhouse\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/#website\",\"url\":\"https:\\\/\\\/blog.aquartia.in\\\/\",\"name\":\"Aquartia Blog\",\"description\":\"Where Ideas Meet Innovation &amp; Awareness\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blog.aquartia.in\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blog.aquartia.in\\\/#\\\/schema\\\/person\\\/8160a5b038855c9fdcc1de41b2310004\",\"name\":\"Siddharth Srivastava\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2aea57ba29e4592ebb546b355e3d509571ec1650b8d284d16baa55203c0c0659?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2aea57ba29e4592ebb546b355e3d509571ec1650b8d284d16baa55203c0c0659?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2aea57ba29e4592ebb546b355e3d509571ec1650b8d284d16baa55203c0c0659?s=96&d=mm&r=g\",\"caption\":\"Siddharth Srivastava\"},\"sameAs\":[\"https:\\\/\\\/blog.aquartia.in\"],\"url\":\"https:\\\/\\\/blog.aquartia.in\\\/index.php\\\/author\\\/get2sid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRIP Scheme: From Generics to Innovation Powerhouse - Aquartia Blog","description":"Explore how India's PRIP Scheme is transforming pharma from generics leader to innovation hub with R&D, biosimilars, precision medicine.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/","og_locale":"en_US","og_type":"article","og_title":"PRIP Scheme: From Generics to Innovation Powerhouse - Aquartia Blog","og_description":"Explore how India's PRIP Scheme is transforming pharma from generics leader to innovation hub with R&D, biosimilars, precision medicine.","og_url":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/","og_site_name":"Aquartia Blog","article_publisher":"https:\/\/www.facebook.com\/aquartiatechnology","article_published_time":"2025-10-31T07:02:44+00:00","article_modified_time":"2025-10-31T07:02:45+00:00","og_image":[{"width":1024,"height":1024,"url":"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/Gemini_Generated_Image_huvjyshuvjyshuvj.png","type":"image\/png"}],"author":"Siddharth Srivastava","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Siddharth Srivastava","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#article","isPartOf":{"@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/"},"author":{"name":"Siddharth Srivastava","@id":"https:\/\/blog.aquartia.in\/#\/schema\/person\/8160a5b038855c9fdcc1de41b2310004"},"headline":"PRIP Scheme: From Generics to Innovation Powerhouse","datePublished":"2025-10-31T07:02:44+00:00","dateModified":"2025-10-31T07:02:45+00:00","mainEntityOfPage":{"@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/"},"wordCount":2914,"commentCount":0,"image":{"@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/Gemini_Generated_Image_huvjyshuvjyshuvj.png","articleSection":["Blog","Medicine"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/","url":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/","name":"PRIP Scheme: From Generics to Innovation Powerhouse - Aquartia Blog","isPartOf":{"@id":"https:\/\/blog.aquartia.in\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#primaryimage"},"image":{"@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#primaryimage"},"thumbnailUrl":"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/Gemini_Generated_Image_huvjyshuvjyshuvj.png","datePublished":"2025-10-31T07:02:44+00:00","dateModified":"2025-10-31T07:02:45+00:00","author":{"@id":"https:\/\/blog.aquartia.in\/#\/schema\/person\/8160a5b038855c9fdcc1de41b2310004"},"description":"Explore how India's PRIP Scheme is transforming pharma from generics leader to innovation hub with R&D, biosimilars, precision medicine.","breadcrumb":{"@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#primaryimage","url":"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/Gemini_Generated_Image_huvjyshuvjyshuvj.png","contentUrl":"https:\/\/blog.aquartia.in\/wp-content\/uploads\/2025\/10\/Gemini_Generated_Image_huvjyshuvjyshuvj.png","width":1024,"height":1024,"caption":"India's PRIP Scheme ignites pharmaceutical R&D, moving beyond generics."},{"@type":"BreadcrumbList","@id":"https:\/\/blog.aquartia.in\/index.php\/2025\/10\/31\/prip-scheme-from-generics-to-innovation-powerhouse\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blog.aquartia.in\/"},{"@type":"ListItem","position":2,"name":"PRIP Scheme: From Generics to Innovation Powerhouse"}]},{"@type":"WebSite","@id":"https:\/\/blog.aquartia.in\/#website","url":"https:\/\/blog.aquartia.in\/","name":"Aquartia Blog","description":"Where Ideas Meet Innovation &amp; Awareness","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blog.aquartia.in\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/blog.aquartia.in\/#\/schema\/person\/8160a5b038855c9fdcc1de41b2310004","name":"Siddharth Srivastava","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/2aea57ba29e4592ebb546b355e3d509571ec1650b8d284d16baa55203c0c0659?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2aea57ba29e4592ebb546b355e3d509571ec1650b8d284d16baa55203c0c0659?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2aea57ba29e4592ebb546b355e3d509571ec1650b8d284d16baa55203c0c0659?s=96&d=mm&r=g","caption":"Siddharth Srivastava"},"sameAs":["https:\/\/blog.aquartia.in"],"url":"https:\/\/blog.aquartia.in\/index.php\/author\/get2sid\/"}]}},"_links":{"self":[{"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/posts\/4333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/comments?post=4333"}],"version-history":[{"count":1,"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/posts\/4333\/revisions"}],"predecessor-version":[{"id":4338,"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/posts\/4333\/revisions\/4338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/media\/4336"}],"wp:attachment":[{"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/media?parent=4333"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/categories?post=4333"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blog.aquartia.in\/index.php\/wp-json\/wp\/v2\/tags?post=4333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}